(Press-News.org) WASHINGTON, DC/LONDON (July 23, 2012) – A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet. These results add to a growing body of evidence that the new regimen could reduce treatment by more than a year for some patients.
The findings from researchers and the non-profit TB Alliance raise hope for a treatment breakthrough amid the growing and dangerous epidemic of drug-resistant forms of TB that, in some cases, are becoming untreatable. The results, presented today at the 2012 International AIDS Conference, also reveal progress in the pursuit of an antiretroviral-compatible TB treatment, which is critical to treating the millions of people with TB/HIV co-infection. Today, TB remains the largest killer of people with AIDS, but very often, TB and HIV treatments cannot be given together because of drug-drug interactions and side effects.
The clinical trial tested a combination of one completely novel drug candidate, a new TB drug candidate already approved to treat other infectious diseases, and one existing TB drug. These results, along with pre-clinical data, suggest that this novel combination could treat both drug-susceptible and some forms of drug-resistant TB in only four months. Currently, people with multi-drug resistant TB (MDR-TB) require 18 to 24 months of treatment. Even those with ordinary TB need six months of taking drugs every day.
"These findings confirm the promise of novel TB regimens to be shorter, simpler, safer, and, compared with today's MDR-TB drugs, much less expensive," said Mel Spigelman, MD, CEO and President of TB Alliance. "The next trial to advance this regimen is already underway. We now have real momentum toward bringing to market treatments that will ultimately help save millions of lives."
TB Alliance's push to test new drugs in combination has been done to produce a regimen that not only would be faster and easier for patients, but also would tackle two other challenges as a major step in stopping the spread of drug-resistant TB—the complexity and high cost of treatment. This promising regimen eliminates the use of injectables and projects to reduce the cost of MDR-TB therapy by as much as 90 percent.
TB is one of the world's most ancient and deadly infectious diseases, dating back thousands of years and found in remains of Egyptian mummies. When HIV/AIDS exploded in the 1980s and 1990s, especially in sub-Saharan Africa, that epidemic triggered a historic jump in the number of TB deaths. An estimated 1.4 million people die from TB, and roughly 9 million people develop the disease, each year. One-third of all people on earth—nearly 2.5 billion people—have a latent form of TB.
The study, NC-001, or New Combination 1, was a two-week trial successfully completed at two centers in South Africa. It involved the new combination therapy called PaMZ, consisting of the novel TB drug candidate, PA-824; moxifloxacin, an established antibiotic not yet approved for use in first-line TB therapy and being developed in partnership with Bayer Healthcare AG; and pyrazinamide, an existing TB drug. NC-001 was funded by the Bill & Melinda Gates Foundation, the United States Agency for International Development, UK aid, and Irish Aid.
"Treating drug-sensitive and drug-resistant TB with the same regimen can simplify the delivery of TB treatment worldwide," said Andreas Diacon, MD, the trial's principal investigator and lead author of the Lancet study. "The results of this study give healthcare providers on the front lines of the TB epidemic hope for better, faster tools needed to stop this disease."
A second trial called New Combination 2 (NC-002) was launched earlier this year to test the PaMZ combination over two months in patients, further advancing it through clinical development. NC-002 is currently enrolling patients and will be conducted at eight sites in South Africa, Tanzania and Brazil, and will build global capacity for TB trials.
In addition to these results, pharmaceutical companies are seeking regulatory approval for individual TB drug candidates—advances made possible by the existence of the most promising research pipeline for TB drugs in history. TB experts say any new drugs for tuberculosis would be an extraordinary development, but that new TB drug combinations are potential game-changers due to their expected impact.
The NC-001 trial also validated the approach to development of novel regimens. Mario Raviglione, MD, Director of the Stop TB Department at the World Health Organization, said testing multiple new TB drug candidates simultaneously has already proven to be a major advance.
"Because of testing drugs in combination, we have already saved several years in the research process to find new, effective regimens to treat TB," Raviglione said. "The results look strongly promising from this early trial. If further testing holds up these results and the regimen is affordable in poor countries, it is huge progress. We could shorten drug regimens substantially for everyone, regardless of whether the form of TB is sensitive or multi-drug resistant. That would be a dramatic step forward."
###
About the Global Alliance for TB Drug Development (TB Alliance):
TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. The TB Alliance operates with funding from the Bill & Melinda Gates Foundation, Irish Aid, UK aid, the United States Agency for International Development, and the United States Food and Drug Administration. For more information, please visit tballiance.org
Neural precursor cells (NPC) in the young brain suppress certain brain tumors such as high-grade gliomas, especially glioblastoma (GBM), which are among the most common and most aggressive tumors. Now researchers of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch and Charité – Universitätsmedizin Berlin have deciphered the underlying mechanism of action with which neural precursor cells protect the young brain against these tumors. They found that the NPC release substances that activate TRPV1 ion channels in the tumor cells and subsequently induce the ...
COLUMBUS, Ohio - In a new study that has implications for distracted drivers, researchers found that people are better at juggling some types of multitasking than they are at others.
Trying to do two visual tasks at once hurt performance in both tasks significantly more than combining a visual and an audio task, the research found.
Alarmingly, though, people who tried to do two visual tasks at the same time rated their performance as better than did those who combined a visual and an audio task - even though their actual performance was worse.
"Many people have this ...
Scientists have discovered a potential cause of Earth's "icehouse climate" cooling trend of the past 45 million years. It has everything to do with the chemistry of the world's oceans.
"Seawater chemistry is characterized by long phases of stability, which are interrupted by short intervals of rapid change," says geoscientist Ulrich Wortmann of the University of Toronto, lead author of a paper reporting the results and published this week in the journal Science.
"We've established a new framework that helps us better interpret evolutionary trends and climate change ...
(Edmonton) A team of University of Alberta researchers has identified a new class of compounds that inhibit the spread of prions, misfolded proteins in the brain that trigger lethal neurodegenerative diseases in humans and animals.
U of A chemistry researcher Frederick West and his team have developed compounds that clear prions from infected cells derived from the brain.
"When these designer molecules were put into infected cells in our lab experiments, the numbers of misfolded proteins diminished—and in some cases we couldn't detect any remaining misfolded prions," ...
Parents are increasingly conscious of the dangers of childhood obesity. There is a growing recognition of health problems associated with extra pounds, including the risk of diabetes, heart disease, and joint and muscle pain.
New research from Tel Aviv University has revealed another significant reason for children to maintain a healthy weight. Dr. Ari Shamiss and Dr. Adi Leiba of TAU's Sackler Faculty of Medicine and the Sheba Medical Center and their fellow researchers found that obesity in adolescence, defined as a Body Mass Index (BMI) in the 85th percentile and ...
Researchers at the Center for Laser Applications at the University of Tennessee Space Institute in Tullahoma have developed a technology that goes on a "seek and destroy" mission for cancerous tumors. They have harnessed the power of lasers to find, map and non-invasively destruct cancerous tumors.
Christian Parigger, associate professor of physics, and Jacqueline Johnson, associate professor of mechanical, aerospace, and biomedical engineering, along with Robert Splinter of Splinter Consultants, have developed the invention. The technology uses a femtosecond laser, ...
Aspirin use appears to reduce the risk of Barrett's esophagus (BE), the largest known risk factor for esophageal cancer, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
"The protective effect of aspirin use appears robust because the analyses suggests a dose-response relationship in which high-dose aspirin was significantly associated with decreased Barrett's esophagus risk," said Chin Hur, MD, MPH, of the Massachusetts General Hospital Institute for Technology ...
A University of Connecticut researcher and his team have discovered that a species of tiny aquatic organism prominent in harmful algal blooms sometimes called "red tide" is even deadlier than first thought, with potential consequences for entire marine food chains.
Professor Hans Dam and his research group in the school's Department of Marine Sciences have discovered that the plankton species Alexandrium tamarense contains not one but two different types of toxins, one that's deadly to large organisms and one that's deadly to small predators.
"If it's killing multicellular ...
Toronto, Canada –
Neuroscientists have found strong evidence that vivid memory and directly experiencing the real moment can trigger similar brain activation patterns.
The study, led by Baycrest's Rotman Research Institute (RRI), in collaboration with the University of Texas at Dallas, is one of the most ambitious and complex yet for elucidating the brain's ability to evoke a memory by reactivating the parts of the brain that were engaged during the original perceptual experience. Researchers found that vivid memory and real perceptual experience share "striking" similarities ...
PROVIDENCE, R.I. [Brown University] — A new study finds that mice have a distinct neural subsystem that links the nose to the brain and is associated with instinctually important smells such as those emitted by predators. That insight, published online this week in Proceedings of the National Academy of Sciences, prompts the question whether mice and other mammals have specially hardwired neural circuitry to trigger instinctive behavior in response to certain smells.
In the series of experiments and observations described in the paper, the authors found that nerve cells ...
